Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION (INCY)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/17/2018 05/18/2018 05/21/2018 05/22/2018 05/23/2018 Date
66.64(c) 67.83(c) 66.79(c) 66.56(c) 66.57(c) Last
1 747 731 1 768 573 1 247 935 1 068 586 848 604 Volume
-0.57% +1.79% -1.53% -0.34% +0.02% Change
More quotes
Financials (USD)
Sales 2018 1 783 M
EBIT 2018 195 M
Net income 2018 93,6 M
Finance 2018 927 M
Yield 2018 -
Sales 2019 2 031 M
EBIT 2019 379 M
Net income 2019 326 M
Finance 2019 1 498 M
Yield 2019 -
P/E ratio 2018 202,53
P/E ratio 2019 44,13
EV / Sales2018 7,39x
EV / Sales2019 6,21x
Capitalization 14 111 M
More Financials
Company
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics.Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI... 
Sector
Biotechnology & Medical Research
Calendar
06/01 | 09:45pmPresentation
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
05/17INCYTE : Reports from Incyte Corporation Highlight Recent Findings in Essential ..
AQ
05/17CALITHERA BIOSCIENCES : Reports First Quarter 2018 Financial Results and Recent ..
AQ
05/11MACROGENICS : Provides Update on Corporate Progress and 1st Quarter 2018 Financi..
AQ
05/04IMMUNOVACCINE INC. : Has Applied to List its Common Shares on Nasdaq, Announces ..
AQ
05/03INCYTE : Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual ..
AQ
05/03Bristol-Myers Squibb Abandons Two Phase III Trials of IDO1 Inhibitor Program
AQ
05/03INCYTE : BMS pulls the plug on Phase 3 trials of IDO1 inhibitor
AQ
05/03INCYTE CORPORATION : Report
CO
05/02INCYTE CORP : Change in Directors or Principal Officers, Submission of Matters t..
AQ
05/02BRISTOL MYERS SQUIBB : drops phase 3 trials of $800M IDO drug
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/11Trump's Plan to Cut Drug Prices Leaves Industry Relieved
DJ
05/09Drugmaker GSK rings in more change as CFO heads for exit in 2019
RE
05/08UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing
RE
05/03Teva raises 2018 outlook, expects migraine drug approval by year-end
RE
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on INCYTE CORPORATION 
INCYTE CORPORATION - 04/19
Attractive price levels
BUY
More Strategies
Latest Tweets
05/23$445.43 Million in Sales Expected for Incyte Co. $INCY This Quarter  
05/22$INCY ALERT: New Incyte Corporation SEC Filing From our Stock News Alerts App 
05/21$INCY D1 filled 4/23 gap - bottom fish with decent base building 
05/20Incyte Co. $INCY Expected to Announce Earnings of $0.12 Per Share  
05/18Contrasting Intrexon $XON & Incyte $INCY  
More tweets
Qtime:97
News from SeekingAlpha
05/15Biotechs Emerge Unscathed And Ready To Go! 
05/14JF'S CORE BIOTECH BUYS #15 : Removal Of A Key Overhang, Buying Weakness In I-O, .. 
05/04ROUNDS REPORT : Exelixis Rallied Due To Positive Earnings While Achaogen Is Set .. 
05/03IDO Appears To Have Wiped Out 
05/01Incyte (INCY) Q1 2018 Results - Earnings Call Transcript 
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 81,0 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-29.71%14 111
CELLTRION, INC.--.--%31 419
IQVIA HOLDINGS INC4.83%21 259
LONZA GROUP1.41%20 379
NEKTAR THERAPEUTICS42.83%14 033
ALNYLAM PHARMACEUTICALS, INC.-20.66%9 948